Synartro – completed treatment of all four cohorts in phase 1/2a clinical study of SYN321

Synartro announced it has completed dosing across all four cohorts in its phase 1/2a study of SYN321, a novel intra‑articular treatment for knee osteoarthritis, with 35 participants dosed in total and the fourth, highest‑dose cohort accounting for 12 patients after an internal safety review approved escalation. The trial, run with CTC at Uppsala University Hospital and initiated on Sept. 1, 2025, has the first two cohorts already completed, the third due to finish imminently, the fourth expected to complete in February 2026, and full study completion targeted for spring 2026. This milestone moves the program into final safety, tolerability, PK and early efficacy data collection, reducing near‑term development risk for a local, sustained‑release OA pain therapy that seeks to avoid systemic side effects.

Analysis

Synartro announced completion of dosing across all four cohorts in its phase 1/2a study of SYN321, with 35 participants dosed in total and the fourth, highest-dose cohort comprising 12 participants after an internal safety review authorized escalation. The trial, initiated on September 1, 2025, is conducted with CTC at Uppsala University Hospital; cohorts one and two have completed participation, cohort three is expected to finish this week, cohort four is expected to complete in February 2026, and full study completion is targeted for spring 2026.

The study is explicitly focused on safety, tolerability, pharmacokinetics and early efficacy signals for SYN321, a local intra‑articular slow‑release candidate for knee osteoarthritis designed to avoid systemic side effects, which makes these readouts binary for near‑term program de‑risking. The internal safety committee’s approval of the highest dose and successful dosing across cohorts modestly reduces early clinical execution risk but does not substitute for formal safety/efficacy data.

Near‑term value drivers are the completion of cohorts three and four and the consolidated safety/PK/early efficacy readouts planned through spring 2026; adverse safety signals or lack of efficacy would materially alter the program outlook. Given the company’s stage, market impact is likely to remain muted and speculative until topline results are released, and major shareholders include founder interests and Linc AB which may influence future financing or partnership moves.

Key Decisions for Investors

• Monitor cohort three and four completion dates and the spring 2026 topline readouts closely, as these results will be the primary de‑risking events
• Treat any new exposure as speculative and size positions conservatively until formal safety and early efficacy data are published, given binary outcomes at this stage
• Be prepared to reassess conviction on publication of safety/PK data—positive readouts could warrant increased allocation for event-driven upside while negative signals should prompt risk reduction or exit
• Watch for corporate updates on partnerships, financing or regulatory interactions leveraged by major shareholders such as Linc AB, as these actions could change dilution or upside potential